Humanized anti-CCR7 receptor antibodies

• US 10,640,565 B2
• Filed: 08/10/2016
• Issued: 05/05/2020
• Est. Priority Date: 08/10/2015
• Status: Active Grant

• Current Assignee: PepMab B.V.
• Original Assignee: PepMab B.V.
• Inventors: Back, Jaap Willem, Boshuizen, Ronald, Puijk, Wouter Cornelis, Turkstra, Johan, Schwamborn, Klaus Heinrich
• Primary Examiner(s): Gangle, Brian
• Assistant Examiner(s): McCollum, Andrea K
• Application Number:
  US15/751,169
• Publication Number:
  US 20180237529A1
• Time in Patent Office: 1,364 Days
• Field of Search: None
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/567 : Framework region [FR]
• CPC Class Codes: C07K 2317/734 : Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/77 : Internalization into the cell
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention provides novel humanized anti-human C-C chemokine receptor type 7 (CCR7) antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.

Claims

1. A humanized anti-C-C chemokine receptor type 7 (anti-CCR7) antibody comprising the hypervariable regions HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3, wherein:

HVR-H1 comprises SEQ ID NO;

6;

HVR-H2 H1 comprises SEQ ID NO;

13;

HVR-H3 H1 comprises SEQ ID NO;

19;

HVR-L1 H1 comprises SEQ ID NO;

27;

HVR-L2 H1 comprises SEQ ID NO;

31; and

HVR-L3 H1 comprises SEQ ID NO;

36,

and wherein antibody has at least one of;

a) a minimal affinity for a synthetic antigen with the amino acid sequence of SEQ ID NO;

76, wherein the minimal affinity is defined by a Kd that is not more than a 10×

higher than the Kd of a mouse anti-CCR7 antibody of which the amino acid sequence of the heavy chain variable domain is SEQ ID NO;

1 and of which the amino acid sequence of the light chain variable domain is SEQ ID NO;

2; and

,

b) an IC50 of no more than 100 nM for inhibiting CCR7-dependent intracellular signalling and/or CCR7 receptor internalization, by at least one CCR7-ligand selected from CCL19 and CCL21.

2. The humanized anti-CCR7 antibody according to claim 1, wherein the heavy chain variable domain of the antibody comprises 4 heavy chain framework regions, HFR1 to HFR4, and 3 hypervariable regions HVR-H1 to HVR-H3 that are operably linked in the order HFR1, HVR-H1, HFR2, HVR-H2, HFR3, HVR-H3 and HFR4, wherein the light chain variable domain of the antibody comprises 4 light chain framework regions, LFR1 to LFR4, and 3 hypervariable regions HVR-L1 to HVR-L3 that are operably linked in the order LFR1, HVR-L1, LFR2, HVR-L2, LFR3, HVR-L3 and LFR4, wherein the heavy chain framework regions HFR1 to HFR4 have the amino acid sequences of:

i) SEQ ID NO'"'"'s;

40, 43, 45 and 48, respectively;

ii) SEQ ID NO'"'"'s;

41, 44, 46 and 49, respectively;

or,

iii) SEQ ID NO'"'"'s;

42, 44, 47 and 49, respectively,

and wherein the light chain framework regions LFR1 to LFR4 have the amino acid sequences of;

iv) SEQ ID NO'"'"'s;

50, 52, 55 and 58, respectively;

or,

v) SEQ ID NO'"'"'s;

51, 53, 56 and 59, respectively.

3. The humanized anti-CCR7 antibody according to claim 1, wherein the heavy chain variable domain of the antibody comprises an amino acid sequence with at least 95% sequence identity to at least one of SEQ ID NO'"'"'s:

61, 62 and 63, and wherein the light chain variable domain of the antibody comprises an amino acid sequence with at least 95% sequence identity to at least one of SEQ ID NO'"'"'s;

64 and 65.

4. The humanized anti-CCR7 antibody according to claim 3, wherein the heavy chain variable domain of the antibody comprises the amino acid sequence of SEQ ID NO:

61 and the light chain variable domain of the antibody comprises the amino acid sequence of SEQ ID NO;

64.

5. The humanized anti-CCR7 antibody according to claim 1, wherein the antibody comprises a heavy chain constant region that is IgG1, IgG2, IgG3 or IgG4 region.

6. The humanized anti-CCR7 antibody according to claim 1, wherein the antibody comprises a functional Fc region possessing at least one effector function selected from the group consisting of:

C1q binding, complement dependent cytotoxicity;

Fc receptor binding, antibody-dependent cell-mediated cytotoxicity and phagocytosis.

7. The humanized anti-CCR7 antibody according to claim 1, wherein the antibody comprises a heavy chain constant region of the allotype G1m17,1.

8. The antibody according to claim 7, wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:

80.

9. A pharmaceutical composition comprising a humanized anti-CCR7 antibody according to claim 1.

10. A method for treating a cancer, in a subject in need thereof comprising administering the humanized anti-CCR7 antibody of claim 1, wherein the cancer is a cancer of which the tumor cells express a CCR7 receptor.

11. A method for treating a cancer, in a subject in need thereof comprising administering the humanized anti-CCR7 antibody of claim 1, wherein the cancer is a cancer of which the tumor cells express a CCR7 receptor.

12. The method of treatment according to claim 10, wherein the cancer is selected from the group consisting of chronic lymphocytic leukaemia (CLL), mantle cells lymphoma (MCL), follicular lymphoma, large B-cell lymphoma, AIDS-associated lymphoma, lymphoplasmacytic lymphoma, Burkitt lymphoma, B-cell acute lymphoblastic leukaemia, Hodgkin'"'"'s disease, adult T-cell leukaemia/lymphoma, mycosis fungoides, blast crisis of chronic myeloproliferative syndromes, blast crisis of myelodysplastic syndromes, breast cancer, non-small cell lung cancer, melanoma, gastric cancer, squamous cell carcinoma of the head and neck and colon carcinoma.

13. A nucleic acid molecule comprising a nucleotide sequence encoding a humanized anti-CCR7 antibody of claim 1.

14. The nucleic acid molecule according to claim 13, wherein the nucleic acid molecule comprises a nucleotide sequence encoding at least one of the heavy chain variable domain and the light chain variable domain of the antibody.

15. The nucleic acid molecule according to claim 14, wherein the coding nucleotide sequence is operably linked to regulatory sequences for expression of the coding nucleotide sequence in a host cell.

16. An isolated host cell comprising the nucleic acid molecule according to claim 13.